Albiglutide (trade name Eperzan) has been approved since March 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2cjcss/albiglutide_type) has announced the addition of the "Albiglutide ...

June 12, 2012 (Philadelphia, Pennsylvania) — Once-weekly albiglutide has a more favorable tolerability profile than once-daily liraglutide, with similar effectiveness; however, albiglutide did ...

A new once-weekly injectable glucagonlike peptide 1 (GLP-1) receptor agonist, albiglutide (Eperzan, GlaxoSmithKline), has been approved in the European Union for the treatment of type 2 diabetes.

Albiglutide, an experimental diabetes drug that GlaxoSmithKline acquired when it bought Rockville-based Human Genome Sciences, proved effective in late-stage trials ...

LONDON (Reuters) - Britain's biggest drugmaker GlaxoSmithKline said on Thursday it had filed for European approval of its new once-weekly diabetes drug albiglutide, as tries to gain a foothold in ...